Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

CompletedOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Percutaneous Coronary Intervention

Interventions

DRUG

Cangrelor

All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.

Trial Locations (1)

University Federico II of Naples, Napoli

All Listed Sponsors

lead

Federico II University

OTHER

NCT04790032 - Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry) | Biotech Hunter | Biotech Hunter